Immuneering (IMRX) Liabilities and Shareholders Equity (2020 - 2026)

Immuneering's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $214.8 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 323.84% year-over-year to $214.8 million; the TTM figure through Mar 2026 stood at $727.9 million (up 192.29% YoY), while the FY2025 annual figure was $232.0 million, up 340.08% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $214.8 million, down from $232.0 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $241.1 million in Q3 2025, with the low at $40.1 million in Q2 2025.
• The 5-year median for Liabilities and Shareholders Equity is $113.9 million (2023), against an average of $121.4 million.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity tumbled 48.61% in 2024, then soared 340.08% in 2025.
• Immuneering's Liabilities and Shareholders Equity stood at $122.4 million in 2022, then declined by 16.17% to $102.6 million in 2023, then sank by 48.61% to $52.7 million in 2024, then jumped by 340.08% to $232.0 million in 2025, then retreated by 7.4% to $214.8 million in 2026.
• Business Quant data shows IMRX's Liabilities and Shareholders Equity at $214.8 million in Q1 2026, $232.0 million in Q4 2025, and $241.1 million in Q3 2025.